This research aims to explore the relationship between baseline inflammatory markers and clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving treatment with Lutetium-177–PSMA-617.
Observational analysis of baseline inflammatory markers
Assessment of clinical outcomes in treated patients
Data collection from patient records
Higher baseline inflammatory markers correlate with poorer clinical outcomes
Inflammatory biomarkers may serve as useful prognostic indicators.
Abstract
Baseline inflammatory markers are associated with clinical outcomes for patients treated with 177Lu-PSMA-617.
KI fragen
Like
Bookmark
Share
View Full Paper
KI fragen
Like
Bookmark
Share
View Full Paper
Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617 | Synapse